Fig. 2: Vaccine-derived immune serum control of SARS-CoV-2 MA-10 infection in wild-type C1q KO and FcγR I/III/IV KO mice.
a, Scheme of passive transfer, virus challenge and tissue collection. b, Neutralizing antibody responses against SARS-CoV-2 MA-10 using sera from naïve (circles) or Wuhan-1 spike protein vaccinated mice (pooled from animals immunized and boosted with mRNA-1273 or ChAd-SARS-CoV-2-S) (squares). Also shown is serum neutralizing antibody activity from recipient wild-type and FcγR I/III/IV KO mice 1 day after transfer of immune sera. c–g, Twelve-week-old male wild-type, C1q KO and FcγR I/III/IV KO C57BL/6 mice were passively transferred by intraperitoneal injection 60 μl of naïve or vaccine-induced immune sera 1 day before intranasal challenge with 103 FFU of SARS-CoV-2 MA-10. At 4 dpi, viral RNA in the nasal wash (c), nasal turbinates (d) and lungs (f) was quantified, and infectious virus in the nasal turbinates (e) and lungs (g) was determined (bars indicate mean ± standard error of the mean; in order left to right n = 5 (b); n = 6, 6, 7, 7, 6 and 7 (c); n = 6, 6, 7, 7, 6 and 7 (d); n = 6, 6, 7, 7, 6 and 7 (e); n = 6, 6, 7, 7, 6 and 7 (f); n = 6, 6, 7, 7, 6 and 7 (g) mice per group, one experiment (b), two experiments (c–g), dotted lines show limit of detection (LOD)). One-way ANOVA with Tukey’s post-test; NS, not significant; *P = 0.0188 (f); ****P < 0.0001 (g)); additional statistical comparisons are presented in Supplementary Table 3. In c–g, the LOD are weight and volume based, and vary on the basis of the amount of material collected for RNA extraction.
